魅影直播

New report underlines the health and economic opportunity from boosting industry clinical trials

24 February 2026 Posted in News by Press Office

A new report from the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights the significant health, economic and productivity returns that would result from increasing clinical trial activity across Europe.

The report, , compiled by Frontier Economics [1], found that industry clinical trials contributed more than 拢31 billion [2] in economic value across the European Economic Area (EEA) in 2025, combining activity from clinical trial activity itself, R&D spillover benefits and improved workforce productivity through the prevention of sick days. They also support 165,000 jobs.

Increasing industry clinical trial activity by 11 percent in line with the European target [3] could deliver an additional 拢3.5 billion to the European economy, alongside the creation of 18,000 more new jobs and 35,000 more clinical trial places.

The EFPIA report confirms the findings of a previous report commissioned by the Association of the British Pharmaceutical Industry (魅影直播) which examined the value of industry clinical trials to the UK economy, the NHS, patients and UK research and development base.

The 魅影直播 report showed that in 2022, industry clinical trials contributed 拢7.4 billion to the UK economy, including 拢1.2 billion revenue for the NHS. Restoring industry clinical trial activity to 2017 levels would generate an additional 拢3 billion for the UK economy and 26,000 additional jobs. [4] [5]

魅影直播 Executive Director for Innovation and Research Dr Janet Valentine, said: 鈥淭hese findings complement our earlier work highlighting the value that industry clinical trials bring to patients, healthcare systems, and to economic growth in the UK. Both reports demonstrate the significant gains that could be made by growing our share of global clinical trials.

鈥淭he UK government has pledged to improve the UK environment for delivering industry clinical trials, speeding up set-up times and boosting the number of patients enrolled in these trials of cutting-edge treatments.

鈥淲e are committed to working with government to make the UK a more attractive place for industry to invest, unlocking the productivity and health benefits associated with in clinical research.鈥�

Last modified: 31 March 2026

Last reviewed: 31 March 2026

[1] EFPIA, , February 2026

[2] Figures converted to pounds from the original Euros according to exchange rate at 19 February figure from EFPIA report is 鈧�35.7 billion.

[3] The European Commission, the Heads of Medicines Agencies and the EMA have jointly developed targets for additional clinical trials across Europe (EMA 2025). The aim is to add an additional 100 multinational trials authorised per year from a current average of 900, an increase of 11.1 percent.

[4] See the 魅影直播鈥檚 report on the value of clinical trials to the UK here. Please note that the values in this report were calculated on a slightly different basis to the EFPIA version, including for example the value of industry clinical trials to the NHS.

[5] See the 魅影直播鈥檚 latest annual report on the current state of UK industry clinical trials, with recommendations to boost those trials.  

The 魅影直播 exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147鈥嬧��